Trial Profile
Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 18 Apr 2019
Price :
$35
*
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms OTIVACTO
- Sponsors Boehringer Ingelheim
- 13 Oct 2017 Planned End Date changed from 30 Mar 2018 to 30 Nov 2017.
- 13 Oct 2017 Planned primary completion date changed from 30 Mar 2018 to 30 Nov 2017.
- 13 Oct 2017 Status changed from recruiting to discontinued.